Teva Stripped of Generic Celebrex Exclusivity

Dec. 18, 2014

A U.S. appeals court has overturned the FDA decision that granted Teva Pharmaceuticals 180-day exclusivity for the generic version of Pfizer's arthritis treatment, Celebrex.

This will delay Teva's generic launch until June 2015, and give Teva's rivals, including Mylan, Watson and Lupin, the the opportunity to also launch generic versions of Celebrex.

While Teva was the first to file its Celebrex generic with the FDA, the court ruled that the patent for Celebrex had expired and consequently, Teva was not entitled to the exclusivity.

Read the Jewish Business News article